Press Release: Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

Dow Jones
22 Apr

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments.

 
What:            Stereotaxis first quarter 2025 financial results conference 
                  call 
 
When:            Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT) 
 
Dial In Number:  To access the live call, dial 800-715-9871 (US and 
                  Canada) or 1-646-307-1963 (International) and give 
                  the participant pass code 4794777. 
 
Webcast:         To access the live and replay webcast, please visit 
                  the investor relations section of Stereotaxis' website 
                  at http://ir.stereotaxis.com/. 
 
Call Replay:     A phone replay of the call will be available for one 
                  month beginning approximately four hours following 
                  the end of the call. To request access for a replay 
                  of the conference call, please click here. 
 
 

About Stereotaxis

Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts: 
David L. Fischel 
Chairman and Chief Executive Officer 
 
Kimberly Peery 
Chief Financial Officer 
 
314-678-6100 
Investors@Stereotaxis.com 

(END) Dow Jones Newswires

April 22, 2025 07:00 ET (11:00 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10